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1 90 100 N/A 100 N/A 100 N/A
2 87 74 N/A 0 N/A N/A N/A
3 100 100 100 100 100 100 100
4 78 91 10 87 N/A 86 52
5 65 45 0 10 14 N/A N/A
6 100 >95 100 87 100 89 >95
7 >95 94 100 100 100 N/A N/A
8 10 0 0 N/A N/A N/A N/A
9 0 N/A N/A N/A N/A N/A N/A
10 100 41 0 N/A N/A N/A N/A
11 N/A N/A N/A N/A N/A N/A N/A
Number describes percentage of donor DNA.362
PHASE II PROSPECTIVE MULTICENTER STUDY OF TREOSULFAN BASED
REDUCED INTENSITY CONDITIONING IN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
FROM 10/10 HLA IDENTICAL UNRELATED DONOR
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Harousseau, J.-L.3, Mohty, M.4, Yakoub-Agha, I.5, Buzyn, A.6,
Milpied, N.7, Nicolini, F.E.1, Labussiere, H.1, Baumgart, J.8, Tabrizi, R.9,
Blaise, D.10 1Hematology, Hopital Edouard Herriot, Lyon, France; 2Service
d’Hematologie Clinique, CHU Estaing; 3Haematology, Centre Anticancer-
eux Rene Gauducheau, Saint Herblain, France; 4CHU de Nantes, Nantes,
France; 5Hematology, CHU de LILLE, Lille, France; 6Hematology, Hopital
Necker, Paris, France; 7Hematology, Hopital Haut-Leveque, Pessac, France;
8MEDAC,Wedel, Germany; 9Hematologie Clinique et de Therapie Cellu-
laire, Hopital du Haut-Leveque, Pessac, France; 10Institut Paoli Calmettes,
Marseille, France
To evaluate the toxicity and efficacy of a RIC regimen including
Treosulfan, followed by allo-HSCT from a 10/10HLA identical un-
related donor, we conducted a prospective study in adult patients
presenting a hematological malignancy in need of allo-HSCT.
The conditioning included: Treosulfan 12g/m2/day iv (day-6 to
day-4), fludarabine 30mg/m2/day iv (day-6 to day -2) and ATG 2.5
mg/kg/day (day-2 to day-1). Peripheral stem cells were used as
HSC source. We included 56 patients, 30 (54%) males and 26 fe-
males with a median age of 57 years (18-65.5). There were 29
AML (14 in CR1, 14 CR2 & 1 \ CR), 8 MDS (1CR1 and 7\
CR) and 1 CML in CR1], 9 MM in PR, 6 CLL (2CR1 & 4PR)
and 3 ALL (1CR1 & 2CR2)]. Among 45 explored for cytogenetics,
23 (51%) were normal and 22 with poor prognostic. Before trans-
plantation, two patients did not receive any previous treatment, 21
received 1 line, 22 two lines and 11 . 2 lines, 49% of patients
were sex-mismatched. For CMV, 43% were -/-, 25% +/+, 28%
+/2 and 1% -/+. For ABO matching, 24% had major incomp. &
24% minor incopm. The median interval diagnosis-allograft was
15 months (4-168). Fifty-four (96%) patients engrafted with a me-
dian time to neutrophils and platelets recovery of 16 days (4-86),
11 (4-82) respectively, 17 patients developed aGVHD grade $ II
with a cumulative incidence at 3 months of 31% (25-38). The cumu-
lative incidence of cGVHD was, at 12 months: 32% (25-39) limited
and 6% (2-10) extensive; at 18 months: 34% (27-47) limited and 8%
(5-12) extensive. After a median follow-up of 13 months (1-57), the
median OS was not reached with a 3 years probability of 52% (38-
71). The median time of EFS was 15 months (8 - 57) with a 3-years
probability of 47% (35-64). The cumulative incidence of relapse at 3
years was 25% (19-31) and the cumulative incidence of TRM at 12,
18 and 36months was 20% (16-27), 23% (16-29) respectively. At the
last follow-up, 22 patients died, 7 due to relapse and 15 due to TRM.
Patients with active cGVHD seem to benefit for the GVL effect on
OS with a high significant difference (HR5 0.2 (0.1-0.6) p5 0.002).
Themultivariate analysis showed: a negative significant impact of both
minor ABO incompatibility (p\ 0.001) and CMV+/2 (p 5 0.01) on
OS, a negative significant impact of patients\CR (p 5 0.03) on re-
lapse. Treosulfan appears to be a good choice for conditioning with
very promising results in terms of OS, relapse and TRM with an
impressive GVL effect.363
NONMYELOABLATIVE HLA-HAPLOIDENTICAL BONE MARROW TRANS-
PLANTATION (HAPLO-BMT)WITHPOST-TRANSPLANTHIGH-DOSECYCLO-
PHOSPHAMIDE (CY) IN PATIENTS WITH SEVERE HEMOGLOBINOPATHIES
Bola~nos-Meade, J.1, Lanzkron, S.2, Kemberling, H.1, Gamper, C.3,
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Introduction: Sickle cell disease (SCD) and other severe hemoglo-
binopathies can be cured with allogeneic BMT. However, the large
majority of patients will have no unaffected HLA-matched siblings
or matched unrelated donors. Over the last decade, we have devel-
oped safe and effective haplo-BMT, facilitated by the discovery
that high-dose post-BMTCy can effectively modulate alloreactivity.
Based on this experience, we studied haplo-BMT in patients with
SCD and other hemoglobinopathies.
Patients and Methods: Ten patients with severe SCD and one with
b-thalassemia (pt 8)were enrolled; 10wereAfrican-American,1 Indian,
7 female, and 4 male. The median age was 25 (16-33). Severe disease
was defined as transfusion–dependence, a history of stroke, more
than 2 hospital admissions per year to the hospital due to pain crisis,
acute chest syndrome, etc. Patients received ATG 0.5mg/kg day -9
and 2mg/kg days -8,-7, fludarabine 30mg/m2 days -6 to -2, Cy
14.5mg/kg on -6 and -5, TBI 20Gy on day -1. Unmanipulatedmarrow
was given on day 0. GvHD prophylaxis consisted of Cy 50mg/kg on
days 3 and 4, and tacrolimus to maintain a level of 5-15ng/dl (for one
year) and MMF 1g TID (until day 35) were started on day 5. Patient
4 was found to have anHLA-matched sibling who served as the donor.
Results: Pts 1 and 2 were transplanted before ATGwas instituted, but
otherwise received the same protocol. The median CD3/kg recipient
dose administered was 3.55x10^7 and nucleated cells/kg recipient ad-
ministered was 3.8x10^8. No cases of acute/chronic GvHD have been
diagnosed. Three cases of PRES were seen, and 1 patient demonstrated
CMV reactivation (pt 10) but not CMV disease. Although primarily an
outpatient protocol, all patients required hospital admissions for pain
control or fever. An absolute neutrophil count. 500/mL was achieved
at a median of 17 (0-45) days and unsupported platelets . 50K/mL at
a median of 23 (0-74) days. Three patients rejected the graft (1 primary
and 2 secondary), fully reconstituting with host hematopoiesis. Myeloid
and CD3 engraftment in peripheral blood are shown in the Table.
At a median follow up is 406 (27-1365) days, all patients are alive and 6
are off immunosupression.Conclusions: Non-myeloablative haplo-BMT with post-BMT Cy is
safe and effective in patients with hemoglobinopathies. Although no
GVHD was seen, graft failure and PRES occurred in 3 patients each.
Except for pain, no other complications of sickle cell disease were seen.
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MINOR ABOMISMATCH IS ASSOCIATEDWITH INCREASED NON-RELAPSE
MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION
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Introduction: Minor ABO mismatch occurs when donors possess
pre-existing immunity to recipient ABO antigens. This combination
presents a risk for clonal expansion of donor B lymphocytes targeting
discrepant ABO antigens after allogeneic hematopoietic cell
transplantation (HCT).
Material and Methods: 1594 patients underwent allo-HCT be-
tween January 1986 and June 2010. Recipient age ranged 0-74 (me-
dian 40) years. 47% underwent allo-HCT for acute leukemia, 13%
for NHL/CLL. 72% received myeloablation, while 28% underwent
reduced-intensity conditioning (RIC). Recipient-donor pairs were
61% ABO matched 18% major mismatched (mm), 17% minor
mm, and 4.5% bidirectional mm. 45% of grafts derived from bone
marrow (BM), 55% from peripheral blood (PB). ABO mm distribu-
tion did not differ by age, disease, conditioning, or graft source.
Median follow-up was 5.7 years.
Results: Compared to ABO matched HCT, OS was inferior across
allminormmpairs (medianOS 2 years vs 7.4 years for ABOmatched,
p\0.0001;CoxHR1.3, 95%CI1.1-1.8, p50.003).Minormmpairs
were found to have significantly increased NRM through day 100
(18% vs 13%, p 5 0.02; HR 1.5, 95%CI 1.06-2.05, p 5 0.02). Im-
paired OS predominated in minor mm receiving BM (HR 1.8, 95%
CI 1.3-2.3, p\ 0.0001) compared with PB grafts (HR 1.1, 95%CI
0.8-1.4, p5 0.59). Interestingly, patients transplanted for acute leu-
kemia exhibited the survival impairment (HR 1.3, 95%CI 1.1-1.6, p
5 0.01) whereas those allografted for NHL/CLL did not (HR 1.1,
95%CI 0.6-1.8, p 5 0.8). OS and NRM differences in the minor
mmpairs did not correlate with conditioning regimen or donor relat-
edness. A trend toward increased acute GVHD was observed in mi-
nor mm recipients (HR 1.3, 95%CI 1.0-1.7; p 5 0.08). Since 2005,
replacement of graft plasma has not ameliorated inferior outcomes
in minor mm HCT, suggesting a cellular etiology. Major mm pairs
did not demonstrate impairments in OS or differences in NRM.
Conclusion: Minor ABO mismatch between recipients and donors
is associated with significantly impaired OS and increased NRM fol-
lowing allo-HCT and should be avoided if possible. In particular,
minor mm BM grafts have inferior outcomes, and we hypothesize
the survival deficit is attributable to increased ABO reactive B cell
content in BM compared with PB. The abrogation of survival im-
pairment in minormmNHLpatients may result from peritransplant
use of Rituximab leading to in vivo depletion of these pathogenic
ABO reactive B cells.365
A PILOT STUDY OF T-CELL DEPLETED ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION WITH BUSULFAN, MELPHALAN, AND
FLUDARABINE CONDITIONING FOLLOWED BY POST TRANSPLANTATION
DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS WITH RELAPSED
MULTIPLE MYELOMA AND HIGH-RISK CYTOGENETICS
Koehne, G.1, Landau, H.1, Hassoun, H.2, Lesokhin, A.2, Lendvai, N.2,
Rosenzweig, M.1, Chung, D.J.2, Young, J.W.1, Giralt, S.1 1Adult Bone
Marrow Transplantation Service; 2Memorial Sloan-Kettering Cancer
Center, New York, NY
Allogeneic hematopoietic stem cell transplantation (allo HSCT) is
a curative therapy for patients (pts)withmultiplemyeloma,but conven-
tional allo HSCT has been associated with unacceptably high rates of
mortality. Non-myeloablative allo HSCT has resulted in high rates
of acute and chronic graft-versus-host disease (GvHD) and progres-
sion.We report initial results of a pilot study of 13 pts, usingT-cell de-
pleted alloHSCT (alloTCDHSCT) fromHLA compatible (matched
related8, matched unrelated3, andmismatched unrelated2) donors. All
13 pts had relapsedmyelomawithin 12mos following autoHSCT, and
12/13 pts had high-risk cytogenetics at diagnosis [t(4;14), t(14;16),
del17p byFISHand/or del13qby karyotyping]. All pts achieved at least
a partial response from preceding chemotherapy or second auto
HSCT. Pts underwent allo TCD HSCT with busulfan (0.8mg/kg x
10 doses), melphalan (70mg/m2 x 2 days), fludarabine (25mg/m2 x 5
days) and rabbit ATG (2.5mg/kg x 2 days). T-cell depletion was per-
formed by positive CD34 selection (Isolex) followed by rosetting
with sheep erythrocytes, achieving\ 103CD3+/kg for all grafts. Allpts engrafted promptly (median d+11, range d+10 to +12). Pts were el-
igible toreceive lowdosesofdonor lymphocyte infusions (DLI) (5x10e5
– 1x10e6 CD3+/kg) no earlier than 5mos post alloHSCT. Five pts are
in continuous complete remission (CR) at 28, 22, 12, 10 and 9mos fol-
lowing allo TCD HSCT. Two of these pts reentered CR following
DLI.Twoptshad stableminimal residual disease for 26 and24mosbe-
fore progression and are being treated with DLI at the current time.
Twopts with refractorymyeloma,whowere transplantedwith residual
16%and10%plasmacells inmarrow,were inCR for 12and8mospost
allo TCD HSCT, developed progression of disease and recently re-
ceivedDLI. 12/13ptswerewithout signsofGvHD,but onepthadpos-
sible superimposed gut GvHD following fulminant C diff colitis. Four
pts died, incl one at 2 mos with oseltamivir-resistant H1N1 infection;
one at 4 mos due to respiratory failure secondary to infection of un-
known etiology, one at 5 mos due to status epilepticus, and one at 6
mos due to acute cerebral hemorrhage.
We are now performing a phase II clinical trial at MSKCC for pts
with relapsed multiple myeloma following auto SCT who had high-
risk cytogenetics at diagnosis or at relapse as well as upfront allo
HSCT for pts with high-risk cytogenetics at diagnosis following
preceding auto SCT.366
SELECTIVELY T CELL DEPLETED ALLOGRAFTS FROM HLA-MATCHED
SIBLING DONORS FOLLOWED BY LOW-DOSE POST TRANSPLANT IMMU-
NOSUPPRESSION TO LIMIT DISEASE RELAPSE IN PATIENTSWITH HEMA-
TOLOGICAL MALIGNANCIES
McIver, Z.A.1, Mielke, S.2, Shenoy, A.3, Fellows, V.4, Stroncek, D.4,
Leitman, S.4, Childs, R.1, Batiwalla, M.1, Koklanaris, E.K.1,
Haggerty, J.1, Savani, B.N.5, Rezvani, K.6, Barrett, A.J.1 1National
Institutes of Health, Bethesda, MD; 2University of Wuerzburg, Wuerz-
burg, Germany; 3Washington Hospital Center, Washington, DC; 4Na-
tional Institutes of Health, Bethesda, MD; 5Vanderbilt University
Medical Center, Nashville, TN; 6Hammersmith Hospital Imperial
College, London, United Kingdom
We evaluated a photodepletion technique to selectively deplete
graft-versus-host disease (GVHD) alloreacting T cells from stem cell
transplants. Donor lymphocytes were stimulated with irradiated in-
vitro expanded recipientT lymphocytes.AlloactivatedTcells preferen-
tially retaining the photosensitizer 4, 5-dibromorhodamine 123
(TH9402) (Kiadis Pharma, NL) were eliminated by light exposure.
Twenty-four patients with hematological malignancies (16 high-risk)
conditioned with fludarabine, cyclophosphamide and total body,
irradiation received a CD34-selected stem cell allograft from an HLA
identical sibling and 5x106/kg selectively depleted (SD) donor T cells.
Low-dose cyclosporine was used as the only post-transplant immuno-
suppression. The overall probability of grade III-IV a-GVHD was
13%. Fourteen patients developed chronic GVHD (c-GVHD). Five
patients relapsed, 2 of whom remain alive in remission after further
treatment. Thirteen patients survive at a median of 22months. Overall
survival and disease free survival probabilities (+/2 SEM) were 43 +/2
13%and 35 +/2 13% respectively. TheSD technique resulted in a low
incidence of relapse (24 +/2 10%), butwas complicated by late non-re-
lapsemortality associated with c-GVHD and infection of 50 +/2 14%
at 4 years follow up. These results suggest that SD may effectively re-
duce severe a-GVHD while conserving graft-versus leukemia effects,
but the depletion strategy has yet to be optimized.367
KIR-HLA GENOTYPES HAVE NO IDENTIFIABLE ROLE IN UNIT PREDOMI-
NANCE FOLLOWING DOUBLE UNIT CORD BLOOD TRANSPLANTATION
Tarek, N.1, Gallagher, M.M.2, Chou, J.F.3, Lubin, M.N.4, Heller, G.3,
Barker, J.N.4, Hsu, K.C.4 1Memorial Sloan Kettering Cancer Center,
New York, NY; 2Sloan Kettering Institute for Cancer Research, New
York, NY; 3Memorial Sloan Kettering Cancer Center, New York, NY;
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Double unit cord blood transplantation (DCBT) is a frequent
strategy to augment graft cell dose. However, in the majority of
